Grossman, D. C. et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA 319, 1901–1913 (2018).
Heijnsdijk, E. A. M. et al. Lifetime benefits and harms of prostate-specific antigen-based risk-stratified screening for prostate cancer. J Natl Cancer Inst 112, 1013–1020 (2020).
Ilic, D. et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 362, k3519 (2018).
Pinsky, P. F., Prorok, P. C. & Kramer, B. S. Prostate cancer screening: a perspective on the current state of the evidence. N Engl J Med 376, 1285–1289 (2017).
Wu, D. et al. Urinary biomarkers in prostate cancer detection and monitoring progression. Crit Rev Oncol Hematol 118, 15–26 (2017).
Chen, J., Oromendia, C., Halpern, J. A. & Ballman, K. V. National trends in management of localized prostate cancer: a population based analysis 2004–2013. Prostate 78, 512–520 (2018).
Loeb, S., Berglund, A. & Stattin, P. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J. Urol. 190, 1742–1749 (2013).
Choo, R. et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J. Urol. 167, 1664–1669 (2002).
Kinsella, N. et al. Factors influencing men’s choice of and adherence to active surveillance for low-risk prostate cancer: a mixed-method systematic review. Eur. Urol. 74, 261–280 (2018).
Descotes, J. L. Diagnosis of prostate cancer. Asian J. Urol. 6, 129–136 (2019).
Fujita, K. & Nonomura, N. Urinary biomarkers of prostate cancer. Int. J. Urol. 25, 770–779 (2018).
Hendriks, R. J., van Oort, I. M. & Schalken, J. A. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostatic Dis. 20, 12–19 (2017).
Dong, M. et al. Urinary glycoproteins associated with aggressive prostate cancer. Theranostics 10, 11892–11907 (2020).
Berman, D. M. & Epstein, J. I. When is prostate cancer really cancer?. Urol. Clin. N. Am. 41, 339–346 (2014).
Eskra, J. N., Rabizadeh, D., Pavlovich, C. P., Catalona, W. J. & Luo, J. Approaches to urinary detection of prostate cancer. Prostate Cancer Prostatic Dis. 22, 362–381 (2019).
Jia, X. et al. Detection of aggressive prostate cancer associated glycoproteins in urine using glycoproteomics and mass spectrometry. Proteomics 16, 2989–2996 (2016).
Pinho, S. S. & Reis, C. A. Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer 15, 540–555 (2015).
Liu, Y. et al. Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. Mol. Cell Proteomics 13, 1753–1768 (2014).
Clark, D. J., Hoti, N., Sun, S. S. & Zhang, H. Comprehensive analysis of protein glycosylation from prostate cancer cells using automated methods to release glycans and glycosite-containing peptides. Glycobiology 26, 1476–1477 (2016).
Clark, D. J. et al. Simple tip-based sample processing method for urinary proteomic analysis. Anal. Chem. 91, 5517–5522 (2019).
Truong, M., Yang, B. & Jarrard, D. F. Toward the detection of prostate cancer in urine: a critical analysis. J. Urol. 189, 422–429 (2013).
Chen, S. Y. et al. Glycans, glycosite, and intact glycopeptide analysis of N-linked glycoproteins using liquid handling systems. Anal. Chem. 92, 1680–1686 (2020).
Dong, M. et al. Development of parallel reaction monitoring assays for the detection of aggressive prostate cancer using urinary glycoproteins. J. Proteome Res. 20, 3590–3599 (2021).
Chen, R. C. et al. Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology clinical practice guideline endorsement. J. Clin. Oncol. 34, 2182–2190 (2016).
Sanda, M. G. et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J. Urol. 199, 683–690 (2018).
Klotz, L. Contemporary approach to active surveillance for favorable risk prostate cancer. Asian J. Urol. 6, 146–152 (2019).
Rittenhouse, H., Blase, A., Shamel, B., Schalken, J. & Groskopf, J. The long and winding road to FDA approval of a novel prostate cancer test: our story. Clin. Chem. 59, 32–34 (2013).
Stephan, C., Ralla, B. & Jung, K. Prostate-specific antigen and other serum and urine markers in prostate cancer. Biochim. Biophys. Acta 1846, 99–112 (2014).
Rodriguez, M. et al. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol. Cancer 16, 156 (2017).
Zhao, F. et al. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer. Clin. Epigenet. 10, 147 (2018).
Leyten, G. H. et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur. Urol. 65, 534–542 (2014).
O’Reilly, E. et al. epiCaPture: a urine DNA methylation test for early detection of aggressive prostate cancer. JCO Precis. Oncol. 3, 1–18 (2019).
Connell, S. P. et al. A four-group urine risk classifier for predicting outcome in prostate cancer patients. BJU Int. https://doi.org/10.1111/bju.14811 (2019).
Dijkstra, S. et al. Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics: a decision analytical model. BJU Int. 120, 659–665 (2017).
Donovan, M. J. et al. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis. 18, 370–375 (2015).
Kim, Y. et al. Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer. Nat. Commun. 7, 11906 (2016).
Chuang, T. D. et al. Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth. J. Biol. Chem. 285, 23598–23606 (2010).
Veeramani, S. et al. Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr. Relat. Cancer 12, 805–822 (2005).
Ergun, A., Lawrence, C. A., Kohanski, M. A., Brennan, T. A. & Collins, J. J. A network biology approach to prostate cancer. Mol. Syst. Biol. 3, 82 (2007).
Whitworth, H. et al. Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen. PLoS ONE 7, e38950 (2012).
Ward, Y. et al. LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Res. 71, 7301–7311 (2011).
Li, Q. K. et al. Improving the detection of aggressive prostate cancer using immunohistochemical staining of protein marker panels. Am. J. Cancer Res. 12, 1323–1336 (2022).
Stark, J. R. et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?. J. Clin. Oncol. 27, 3459–3464 (2009).